Essential role for dnmt1 in the prevention and maintenance of MYC-Induced T-Cell lmphomas

Molecular and Cellular Biology

Volumn 33, Issue 21, 2013, Pages 4321-4333

  Peters, Staci L ^a   Hlady, Ryan A ^b   Opavska, Jana ^b   Klinkebiel, David ^a   Novakova, Slavomira ^b,e   Smith, Lynette M ^b   Lewis, Robert E ^b   Karpf, Adam R ^b   Simpson, Melanie A ^c   Wu, Lizhao ^d   Opavsky, Rene ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL MATURATION; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE; H2 AB1 GENE; HEMATOPOIESIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; T CELL LYMPHOMA; TUMOR CELL;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOMA, T-CELL; MICE; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84886924910     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00776-13     Document Type: Article

References (62)

1. Poetsch AR, Plass C. 2011. Transcriptional regulation by DNA methylation. Cancer Treat. Rev. 37:S8-S12.
2. Shenker N, Flanagan JM. 2012. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br. J. Cancer 106: 248-253.
3. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
4. McCabe MT, Brandes JC, Vertino PM. 2009. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin. Cancer Res. 15: 3927-3937.
5. Robertson KD. 2005. DNA methylation and human disease. Nat. Rev. Genet. 6:597-610.
6. Portela A, Esteller M. 2010. Epigenetic modifications and human disease. Nat. Biotechnol. 28:1056-1068.
7. Fernandez AF, Huidobro C, Fraga MF. 2012. De novo DNA methyltransferases: oncogenes, tumor suppressors, or both? Trends Genet. 28: 474-479.
8. Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257.
9. Borgel J, Guibert S, Li Y, Chiba H, Schübeler D, Saskie H, Forne T, Weber M. 2010. Targets and dynamics of promoter DNA methylation during early mouse development. Nat. Genet. 42:1093-1100.
10. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, Macleod AR. 2003.DNMT1is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33:61-65.
11. Vertino PM, Yen RW, Gao J, Baylin SB. 1996. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine- 5-)-methyltransferase. Mol. Cell. Biol. 16:4555-4565.
12. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. 2003. Predicting aberrant CpG island methylation. Proc. Natl. Acad. Sci. U. S. A. 100: 12253-12258.
13. Arand J, Spieler D, Karius T, Branco MR, Meilinger D, Meissner A, Jenuwein T, Xu G, Leonhardt H, Wolf V, Walter J. 2012. In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. PLoS Genet. 8:e1002750. doi:10.1371/journal.pgen.1002750.
14. Fuks F, Bergers WA, Brehm A, Hughes-Davies L, Kouzarides T. 2000.DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24:88-91.
15. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:338-342.
16. Rountree MR, Bachman KE, Baylin SB. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:269-277.
17. The Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337.
18. Grasso CS, Wu Y0 Rosincon MDR, Cao X, Dhanasekaran M, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243.
19. The Cancer Genome Atlas Research Network. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368:2059-2074.
20. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. 2001. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U. S. A. 98: 15149-15154.
21. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J, Olofsson T, Rade J, Fontes M, Porwit-Macdonald A, Behrendtz M, Hoglund M, Johansson B, Fioretos T. 2007. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 21:1198-1203.
22. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenisch R. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 102:13580-13585.
23. Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR. 2010. Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol. Cell. Biol. 30:4159-4174.
24. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. 2012. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 120:e83-e92.
25. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. 2012. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 26:344-349.
26. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300:489-492.
27. Bröske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, Kuhl C, Enns A, Prinz M, Jaenisch R, Nerlov C, Leutz A, Andrade-Navarro MA, Jacobsen SE, Rosenbauer F. 2009. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 41:1207-1215.
28. Mao X, Fujiwara Y, Chapdelaine A, Yang H, Orkin SH. 2001. Activation of EGFP expression by cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 97:324-326.
29. Perl A, Wert SE, Nagy A, Lobe CG, Whitsett JA. 2002. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl. Acad. Sci. U. S. A. 99:10482-10487.
30. Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J, Hannah J, Iqbal J, Anderson KM, Siebler HM, Smith LM, Greiner TC, Bastola D, Joshi S, Lockridge O, Simpson MA, Felsher DW, Wagner KU, Chan WC, Christman JK, Opavsky R. 2012. Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J. Clin. Invest. 122:163-177.
31. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, Church GM. 2009. Targeted and genome-scale strategies reveal genebody methylation signatures in human cells. Nat. Biotechnol. 27:361-368.
32. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-140.
33. Robinson MD, Smyth GK. 2007. Moderated statistical tests for assessing differences in tag abundance. Bioinformatics 23:2881-2887.
34. Robinson MD, Smyth GK. 2008. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics 9:321-332.
35. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T. 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23:2700-2704.
36. Song L, James SR, Kazim L, Karpf AR. 2005. Specific method for the determination of genomic DNA methylation by liquid chromatographyelectrospray ionization tandem mass spectrometry. Anal. Chem. 77:504-510.
37. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207-210.
38. Baldi P, Long AD. 2001. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17:509-519.
39. Li LC, Dahiya R. 2002. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431.
40. Opavsky R, Wang SH, Trikha P, Raval A, Huang Y, Wu YZ, Rodriguez B, Keller B, Liyanarachchi S, Wei G, Davuluri RV, Weinstein M, Felsher D, Ostrowski M, Leone G, Plass C. 2007. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet. 3:1757-1769.
41. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404:1003-1007.
42. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, Farrow S, Gilroy DW. 2011. Transcriptomic analyses of murine resolution- phase macrophages. Blood 118:e192-e208.
43. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. 2008. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27:404-408.
44. Trowbridge JJ, Snow JW, Kim J, Orkin SH. 2009. DNA methyltrans-ferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 5:442-449.
45. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A. 2004. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 18:2747-2763.
46. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, Knoepfler PS, Cheng PF, MacDonald HR, Eisenman RN, Bernstein ID, Trumpp A. 2008. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3:611-624.
47. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Pérez-Melgosa M, Sweetser MT, Schlissel MS, Nguyen S, Cherry SR, Tsai JH, Tucker SM, Weaver WM, Kelso A, Jaenisch R, Wilson CB. 2001. A critical role for Dnmt1 and DNA methylation in T-cell development, function, and survival. Immunity 15:763-774.
48. Ginsberg AM, Raffeld M, Cossman J. 1991. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 77:833-840.
49. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
50. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler- McKay P, Brandt SJ, Agulnick A, Nagarajan L. 2010. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 29:3044-3053.
51. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. 1999. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 96:3092-3097.
52. Nepal RM, Zaheen A, Basit W, Li L, Berger SA, Martin A. 2008. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice. Oncogene 27:4752-4756.
53. Connor F, Bertwistle D, Mee JP, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A. 1997. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17:423-430.
54. Martín-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. 2001. Tumor susceptibility of p21 (Waf1/Cip1)-deficient mice. Cancer Res. 61: 6234-6238.
55. Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, Kluin-Nelemans HC, Giphart-Gassler M. 2003. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 22:538-547.
56. Putz G, Rosner A, Nuesslein I, Schmitz N, Buchholz F. 2006. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25:929-939.
57. Hidaka T, Nakahata S, Hatakeyama K, Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K. 2008. Down-regulation of TCF8 is involved in the leukemogenesis of adult Tcell leukemia/lymphoma. Blood 112:383-393.
58. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, Li W, Goodell MA. 2012. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44:23-31.
59. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, Baylin SB. 2012. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res. 40:4334-4346.
60. Lee EJ, Pei L, Srivastava G, Joshi T, Kushwaha G, Choi JH, Robertson KD, Wang X, Colbourne JK, Zhang L, Schroth GP, Xu D, Zhang K, Shi H. 2011. Targeted bisulfite sequencing by solution hybrid selection and massively parallel sequencing. Nucleic Acids Res. 39:e127. doi:10.1093/nar/gkr598.
61. Colaneri A, Staffa N, Fargo DC, Gao Y, Wang T, Peddada SD, Birnbaumer L. 2011. Expanded methyl-sensitive cut counting reveals hypomethylation as an epigenetic state that highlights functional sequences of the genome. Proc. Natl. Acad. Sci. U. S. A. 108:9715-9720.
62. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK. 2010. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363:2424-2433.